Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects

Added 216 days ago (28.04.2021)
Authors: Marja-Riitta Taskinen; Elias Björnson; Linda Andersson; Juhani Kahri; Kimmo Porthan; Niina Matikainen; Sanni Söderlund; Kirsi Pietiläinen; Antti Hakkarainen; Nina Lundbom; Ralf Nilsson; Marcus Ståhlman; Martin Adiels; Paolo Parini; Chris Packard; Jan Borén
Read article